Dubbed CubiCAR, Cellectis' all-in-one construct has an embedded multifunctional tag for the purification, tracking and elimination of CAR-T cells, the company said. A study published in Scientific Reports showed that the CAR-T cells were effectively destroyed by the antibody rituximab in vivo. This could offer oncologists the opportunity to shut down the cells if they spark dangerous immune reactions.